AFP-L3含量测定在肝癌诊治中的意义

Role of AFP-L3 in diagnosis and treatment of hepatocellular carcinoma

目的探讨甲胎蛋白异质体3(AFP-L3)检测在肝细胞癌(HCC)诊治中的临床意义。方法采用ELISA法测定112例肝病患者血清标本人小扁豆素结合型甲胎蛋白(AFP)/AFP-L3的含量。结果 HCC患者的AFP-L3阳性率为81.7%,高于肝硬化组(18.2%)、肝脏良性肿瘤组(10.5%);术后AFP-L3持续阳性的HCC患者1、2、3 a生存率分别为77.3%、45.5%、22.7%,而AFP-L3转阴的HCC患者1、2、3 a生存率分别为75.6%、53.7%、41.5%,两组3 a生存率有显著差异。结论测定AFP-L3对AFP阳性时的良、恶性肝病的鉴别及HCC的早期诊断、预后判断具有重要意义。

Objective To explore the role of alpha-fetoprotein isoform-L3（AFP-L3） as a biomarker in diagnosis and treatment of hepatocellular carcinoma（HCC）.Method AFP-L3 level and alpha-fetoprotein（AFP） level were measured in 112 serum samples by ELISA immunoassay kit.Results The positive rate of AFP-L3 in patients with HCC was 81.7%,which was significantly higher than that of the patients with benign liver tumors（10.5%） and the patients with liver cirrhosis（18.2%）（P0.05）.The 1-year,2-year and 3-year survival rate after operation in AFP-L3 positive group were 77.3%,45.5%,22.7%,while they were 75.6%,53.7%,41.5% in negative group respectively.Conclusion AFP-L3 is a valuable biomarker in diagnosis and prediction of prognosis of HCC.